Wednesday, April 2, 2025

Meliora Therapeutics Establishes Leadership Team with Key Promotion and New Addition

Related stories

Hacking the Hackers: How GenAI is Predicting and Preventing Cyber Attacks

In the high-stakes arena of cybersecurity, the rules of...

Veltris Acquires BPK to Boost AI & Digital in Healthcare

Veltris, a digital product engineering services provider backed by...

Accenture & Schaeffler Advance Industrial Humanoid Robots

Accenture has joined forces with Schaeffler AG to reshape...

EDGNEX Data Centers partners with Hyperco

The acquisition is expected to further strengthen the expansion...

Chef Robotics Raises $43M Series A to Scale AI Robotics

Chef Robotics, a leader in AI-powered robotic systems for...
spot_imgspot_img

Meliora Therapeutics, a machine learning therapeutics company developing novel and transformative cancer drugs, announced the promotion of Claudio Chuaqui, Ph.D., to Chief Scientific Officer (CSO), and the appointment of Anand Selvaraj, Ph.D. as Vice President and Head of Cancer Biology.

Meliora Therapeutics“These leadership updates mark the beginning of a new phase for Meliora. Claudio’s promotion to CSO is a testament to his pivotal contributions to our pipeline and platform. We are also excited to welcome Anand, whose experience in cancer biology will be critical in advancing the company’s mission,” said David Li, co-founder and CEO of Meliora Therapeutics.

Dr. Claudio Chuaqui’s promotion to CSO comes as Meliora rapidly progresses multiple projects in its internal pipeline under his leadership and expertise. Bringing over 20 years of experience in drug discovery, Claudio is a leader with a strong record of delivering drug programs from the exploratory phase to the clinic specifically in oncology. His extensive tenure includes senior positions at Syros, Astrazeneca, Celgene and Biogen, during which he has led projects resulting in the approval of Tagrisso (osimertinib), which is now a mainstay in the treatment paradigm for non small cell lung cancer, as well as numerous other programs that have reached the clinic. He is a computational chemist by training, holding a B.Sc in Chemistry from the University of Manitoba and a Ph.D. in Chemical Physics from the University of Waterloo.

Also Read: ZEPHYRx and NIOX are working together to advance respiratory clinical research

Anand Selvaraj joins Meliora from Novartis, where he served as a Director within the Precision Oncology group and led scientific teams in drug discovery. Prior to Novartis, Anand was instrumental in advancing several cancer drug discovery programs at H3 Biomedicine which led to clinical assets. With 12 years of experience in biotech and pharma, Anand’s experience will be critical in setting and executing against Meliora’s cancer biology scientific strategy.

Meliora Therapeutics is discovering and developing small molecule oncology therapies for high value cancer targets with its proprietary machine learning powered platform, AnchorOmics. Pairing the first multimodal, mechanism-of-action machine learning algorithm and a world-class team of scientists and engineers, Meliora is pioneering a novel approach to create life-changing therapies for cancer patients.

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img